CURRICULUM VITAE

625 views
585 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
625
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

CURRICULUM VITAE

  1. 1. CURRICULUM VITAE<br />Jason M. Foster M.D.<br />Business AddressUniversity of Nebraska Medical Center<br />Department of Surgery<br />Division of Surgical Oncology<br />Associate Professor <br />984030 Nebraska Medical Center<br />Work: (402)559-7272; Fax: (402) 559-7900<br />Email: jfosterm@unmc.edu<br />Education<br />1990-1994Temple University School of Medicine – Philadelphia, PA 19140<br />Doctor of Medicine<br />1986-1990Bucknell University – Lewisburg, PA 17837<br />BS, Chemistry<br />Internship/Residency<br />1994-2002General Surgery: University Hospitals of Cleveland/Case Western Reserve, Cleveland, OH<br />Fellowship<br />2004-2005Gastrointestinal & Mixed Tumor Oncology: Roswell Park Cancer Institute, Buffalo, NY<br />2002-2004Surgical Oncology: Roswell Park Cancer Institute, Buffalo, NY<br />Allen Scholar Basic Science Research Fellowship: University <br />Hospitals of Cleveland/Case Western Reserve, Cleveland, OH<br />Academic Appointments<br />2010- presentAssociate Professor of Surgery: Department of Surgical Oncology, University of Nebraska Medical Center, Omaha, NE<br />2010-presentAdjunct Associate Professor of Surgery: Department of Surgical Oncology, Creighton University, Omaha, NE<br />2006-presentAssistant Professor of Surgery: Department of Surgical Oncology, Creighton University, Omaha, NE<br />2002-2006Clinical Instructor: Department of Surgery, State University of <br />New York at Buffalo, Buffalo, NY<br />Affiliate Clinical Instructor: Department of Surgery, Case Western Reserve University, Cleveland, OH<br />Adjunct Clinical Instructor: Department of Surgery, Case Western Reserve University, Cleveland OH<br />Employment History<br />2002-presentFellow: Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY<br />1997-1999Surgical Staff: Department of Surgery, SUMMA Health Systems, Akron, OH<br />1996-1999Flight Surgeon: Department of Surgery, Metrohealth Medical Center/ Case Western Reserve University, Cleveland, OH<br />Resident: Department of General Surgery, Case Western Reserve University/ University Hospitals of Cleveland, Cleveland, OH<br />1987-1989Summer Internship (Chemist): Mobay Chemical Corporation, Pittsburgh, PA<br />Board Certification and State Licensures<br />2004-currentAmerican Board of Surgery: 48798Exp: 2/9/2014<br />1996-2005 Ohio: 35-07-1662-F<br />2002-current New York: 225358-1Exp: 5/31/2007<br />2005-current Nebraska: 23497Exp: 10/1/2006<br />USMLE I,II,III 6/92,9/93,6/95<br />Special Training<br />2003Sentinel Lymph Node Technique<br />2002-2003Interventional Endoscopy<br />Radiofrequency Ablation techniques<br />2010Single Site Laparoscopic Surgery<br />Awards and Honors<br />2008, 2009Patient’s Choice Award Physicians<br />2008CUMC Hospital Promising Young Physician<br />1999Outstanding Young Americans<br />1998-1999NIH K-12 Translation Research Oncology Research Grant <br />1996-1998NIH K-12 Research Oncology Training Grant<br />1996-1999 Dudley P. Allen Scholar Fellow, CWRU Dept of Surgery<br />2nd place Abstract/Presentation at 36th Annual Cleveland Surgical Society<br />1995Invitation to AACR Molecular Biology Workshop<br />1990Temple University Scholars Physiology<br />Scientific and Medical Societies<br />2006North Central Cancer Treatment Group<br />2005 Creighton Medical Society<br />American Society of Clinical Oncology<br /> Society of Surgical Oncology <br />2001American College of Surgeons<br />2000American Medical Association<br />American Association for Cancer Research<br /> Student National Medical Association <br />National Medical Association<br />Committees and Organizations<br />2008-currentMy Sister Keeper Breast Cancer Survivors Board of Directors<br />2008-currentCreighton University Colorectal Community Task Force for Screening and Prevention<br />2007-current Creighton University Medical School Education Environment <br /> Task Force Committee<br />2007-currentCreighton Hospital Pharmacy & Therapeutics Anticoagulation Committee<br />2006-2008Creighton University Committee on Cancer<br />Association of Residents and Fellows President<br />Graduate Medical Education Council Delegate<br />SNMA hospital delegate<br />Minority House Staff Organization Co-president<br />CWRU Advanced anatomy instructor for 4th year students<br />Clinical Interests<br />Gastrointestinal malignancies – pancreas, biliary, gastric, metastatic liver, CRC<br />Endocrine – pancreas, thyroid, adrenal, carcinoid<br />Melanoma<br />Hyperthermic therapy – IPHC (carcinomatosis) and ILP (melanoma)<br />Current Research Projects<br />Discovery of Prognostic Factors and Therapeutic Targets in Malignant Peritoneal Mesothelioma through the Identification of Gene Mutations and Molecular Pathway Perturbations <br />Biological events and molecular signature of EGFR mutations in malignant mesothelioma cancer cells <br />Efficacy of EGFR-TK inhibitors in mesothelioma tumors with and without EGFR mutations<br />Investigation of the biological mechanism of tumor maintenance in colorectal tumors with overexpression of mucin glycoproteins (MUC-1, MUC-2) <br />Role of hyperthermia in cancer therapy <br />Research Funding/Grants<br />$225,000Health Futures Foundations Grant<br />Creighton University/State of Nebraska<br />2006-2010$75,000Center of Excellence Grant<br />Creighton University<br />2007-2009$200,000LB595<br />Creighton University/State of Nebraska<br />Research Project<br />1996-1999Investigation of the autocrine and paracrine biological effects of growth factor TGF perturbations in colon cancer that facilitate and inhibit tumor progression<br />Principal Investigator: J. K. V. Willson M.D.<br />Ireland Cancer Center, Case Western Reserve University<br />1996-1999Investigation of the autocrine and paracrine biological effects of TGF up-regulation that facilitates colon cancer progression<br />Principal Investigator: J. K. V. Willson M.D.<br />Ireland Cancer Center, Case Western Reserve University<br />1991-1993Role of free radicals in ischemic brain injury and the protective effects of antioxidants<br />Preceptor: Ron Tuma PhD.<br />Temple University School of Medicine<br />1990-1993Role of neutrophils in the exacerbation of cerebral ischemia and the protective effects of neutropenia<br />Preceptor: Ron Tuma PhD.<br />Temple University School of Medicine<br /> <br />Publications: Peer Reviewed<br />Jaing, D, Yang H, Willson JKV, Liang J, Humphrey LE, Zborowska E, Wang D, Foster J, Fan R, Brattain MG. AutocrineTransforming Growth Factor  Provides a Growth Advantage to Malignant Cells by Facilitating Re-entry into the Cell Cycle from Suboptimal Growth States, 1998, The Journal of Biological Chemistry 273, 31471-9.<br />Ye SC, Foster JM*, Li WH, Liang JR, Zborowska E, Venkateswarlu S, Gong JG, Brattain MG, Willson JKV. Contextual Effects of TGF on the Tumorigenicity of Human Colon Carcinoma. 1999, Cancer Research 59, 4725-31.<br />Hurd TC, James T, Foster JM*. Factors Affecting Breast Cancer Treatment: Underserved and Minority Populations. 2005, Surgical Oncology Clinics of North America 14(1), 119-30.<br />Palesty JA, Foster JM*, Hurd TC, Watroba N, Rezaishiraz H, Edge SB. Axillary Recurrence in Women with a Negative Sentinel Lymph Node and No Axillary Dissection in Breast Cancer. 2006, Journal of Surgical Oncology 93, 129-32<br />Foster JM, Integan M, Litwin A, Kuvshinoff B, Gibbs JF. The utilization of laparoscopy to diagnose regenerative nodular hyperplasia, the “great masquerader” of liver tumors. 2006, J Gastrointest Surg 10(5), 727-33<br />Javle M,Yu J, Khoury T, Chadha K, Iyer RV, Kuvshinoff B, Gibbs JG, Geradts J, Foster JM, Black J, Brattian M. Akt expression may predict favorable prognosis in cholangiocarcinoma. 2006, Journal of Gastroenterology and Hepatology 21, 1744-51<br />J. Esquivel, R. Sticca, P. Sugarbaker, E. Levine, T.D. Yan and The Peritoneal Surface Malignancy Group: Foster J et al Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement. 2006, Ann Surg Onc 14(1), 128-33<br />Foster JM, Hoshi H, Chu Q, Smith JL, Driscoll D, Nava HR, Gibbs JF. Radical re-resection is indicated for all T2 and T3 gallbladder and results in the same survival as primarily resected gallbladder cancers. 2006, Ann Surg Onc 14(2), 833-40<br />Rajput A, Koterba AP, Kreiserg JI, Foster JM, Willson JKV, Bratttain M. A novel EGFR antagonism in vivo. 2007, Cancer Res. Jan 15;67(2):665-73<br />Foster J, Black J, LeVea C, Khoury T, Kuvshinoff B, Javle M, Gibbs JF. Cox-2 expression and EGFR expression with downstream pathway activation are prognostic predictors in hepatocellular carcinoma and are potential targets for biological therapies. 2007, Ann Surg Oncol. Feb;14(2):752-8. Epub 2006 Dec 5<br />Foster JM, Filacoma P, Brady, W, Nava H, Hicks W, Rigual N, Smith J, Loree T, Gibbs JF. The ‘Push’ technique is a safe method for placing percutaneous endoscopic gastrostomy tubes in head and neck cancer patients. 2007, Surg Endosc. Jun;21(6):897-901. Epub 2006 Dec 16<br />Gatalica Z, Foster JM, Loggie BW. HPV associated pseudomyxoma peritonei. Croat Med J. 2008 Oct;49(5):669-73.<br />Foster JM, Gatalica, Z, Lilleberg S, Haynatzki G, Loggie, BW. Novel and existing mutations in the EGF receptor tyrosine kinase domain are predictors of optimal resectability in malignant peritoneal mesothelioma. Ann Surg Oncol. 2009 Jan;16(1):152-8. Epub 2008 Nov 8 <br />Lynch H, Steve Lanspa S, Sharma P. Gatalica Z, Foster JM. FAP, Gastric Cancer, and Genetic Counseling Featuring Children and Young Adults: A Family Study and Review. Accepted Journal of Hereditary Cancer 2010.<br />Foster JM, Uppala R, Carreau JH, Gatalica, Z, Lilleberg S, Loggie, BW. Novel and existing functional mutations in the EGF receptor tyrosine kinase domain are predictors of outcome in malignant peritoneal mesothelioma. Accepted World Journal of Surgical Oncology 2010.<br />Chadha KS, Thatikonda C, Schiff M, Miller A, Foster JM, Nava H, Sitrin MD. Outcomes of Percutaneous Endoscopic Gastrostomy Tube Placement using the Brown-Muller T-fastener technique in Head and Neck and Esophageal Cancer Patients. Submitted Journal of Parenteral and Enteral Nutrition 2010.<br />Gupta P*, Carreau J*, Loggie, BW, Grotz TE, Gatalica, Z, Sharma P, Foster JM. Routine right hemicolectomy (RHC) may not be indicated in pseudomyxoma peritonei/mucinous appendiceal neoplasm (PMP/MAN). Submitted Journal of Surgical Oncology 2010<br />Foster JM, Grotz TE, Turaga KK, Gatalica, Z, Sharma P, Loggie, BW. Analysis of immunohistochemical predictors of outcome in pseudomyxoma peritonei. Submitted 2010<br />El,-Abaseri T, Loggie BW, Foster JM. Novel illustration that MUC-2 over-expression promotes tumor growth by autocrine cellular events and signaling. Submitted Journal of Clinical Investigation 2010<br />Publications: Book Chapters<br />Yi, B, Foster JM, Loggie BW. Hyperthermic Intraperitoneal Chemotherapy in Nongynecologic Cancer. Current Clinical Oncology: Intra-peritoneal Cancer Therapy. 2007<br />Publications in preparation<br />Foster JM, Nava H, Hicks W, Loree T, Rigual N, Kuvshinoff B, Gibbs JF. Indications for pre- or peri- percutaneous endoscopic gastrostomy tubes (PEG) and predictors of prolonged enteral feeding in head and neck cancer patients treated with surgical extirpiration <br />Palesty JA, Foster JM, Kraybill WG, Banka T, Sheldon DG, Driscoll D, Kane JM. Melanoma patients and incidence of non-melanoma malignancies. <br />Foster JM, Blaus J, Carreau JH, Gupta P, Loggie BW. Efficacy of Dextran prophylaxis in peritoneal cytoreduction surgery<br />Crocket, D, Subbiah S, Csordas, A, Foster JM. Efficacy of Imatinib in the setting of malabsorption and subtherapeutic Imatinib levels. <br />Crocket D, Hunter W, Subbiah S, Silberstein P, Loggie BW, Foster JM. Efficacy of Imatinib in metastatic DFSP. <br />Foster JM, Bathla P, Gatalica Z, Sharma P, Loggie BW. Should cytroreductive surgery be performed in patients with signet cell carcinomatosis?<br />Foster JM, Sharma P, Gatalica Z, Loggie. Outcome of patients with goblet cell carcinoid carcinomatosis treated with cytoreductive surgery and intra-peritoneal hyperthermic chemotherapy<br />Carreau JH, Blaus J, Grotz T, Gatalica Z, Sharma P, Loggie BW, Foster JM. Safety of Cytoreductive surgery & HIPEC in the setting of neoadjuvant chemoterhapy.<br />Foster JM, Gatalica Z, Silva E, Loggie BW. Phase II evaluation of Carboplatin intra-peritoneal hyperthermia in recurrent ovarian cancer <br />Gupta P, Lindau R, Loggie BW, Foster JM. Utility of second look laparoscopy in appendiceal neoplasms.<br />Lindau R, Gupta P, Gatalica, Loggie BW, Foster JM. Cytoreductive surgery and IPHC in pancreatic carcinomatosis <br />Published Abstracts and Presentations<br />1. Foster JM, Willis J, Brattain MG, Willson JKV. TGF overexpression results in in vivo progression of colon cancer cells. 36th Annual Cleveland Surgical Society 1998<br />2. Foster JM, Willis J, Brattain MG, Willson JKV. TGF overexpression results in in vivo progression of weakly tumorigenic human colon cancer cells. Digestive Disease Week 1998<br />3. Foster JM, Willis J, Venkaeswarlu S, Lin Y, Ferguson K, Zboroskwa E, Brattain MG, Willson JKV. Ectopic TGF expression in colon non-tumorigenic cancer cells results in in vivo progression by induction of angiogenesis, proliferation and the inhibition of apoptosis. 90th Annual AACR Meeting 1999 <br />4. Hoshi H, Foster JM, Chu Q, Kuvshinoff B, Rajput A, Driscoll D, Nava HR, Gibbs JF. Radical re-resection is indicated for all T2 and T3 gallbladder and results in the same survival as primarily resected gallbladder cancers. Society of Surgical Oncology 2004<br />5. Foster JM, Hoshi H, Chu Q, Kuvshinoff B, Rajput A, Driscoll D, Nava HR, Gibbs JF. Radical re-resection is indicated for all T2 and T3 gallbladder and results in the same survival as primarily resected gallbladder cancers. Winter Gastrointestinal American of Clinical Oncology (ASCO-GI) 2005<br />6. Foster JM, Black J, LeVea C, Kuvshinoff B, Gibbs JF, Javle M. COX-2 and EGFR expression are common in hepatocellular carcinoma supporting biological targeted therapy directed at these pathways. Winter Gastrointestinal American Society of Surgical Oncology (ASCO-GI) 2005<br />7. Palesty JA, Foster JM, Kraybill WG, Banka T, Sheldon DG, Driscoll D, Kane JM. Melanoma patients and incidence of non-melanoma malignancies. Society of Surgical Oncology 2005 <br />8. Rajput A, Wang J, Foster JM, Dawson D, Willis J, Bratttain M, Wilson JKV. The role of autocrine transforming growth factor alpha in epidermal growth factor receptor mediated tumorigenicity. Society of University Surgeons 2006<br />9. Foster JM, Black J, LeVea C, Khoury T, Kuvshinoff B, Javle M, Gibbs JF. Cox-2 expression and EGFR expression with downstream pathway activation are prognostic predictors in hepatocellular carcinoma and are potential targets for biological therapies. Winter Gastrointestinal American Society of Clinical Oncology (ASCO-GI) 2006<br />10. Foster JM, Black J, LeVea C, Khoury T, Kuvshinoff B, Javle M, Gibbs JF. Cox-2 expression and EGFR expression with downstream pathway activation are prognostic predictors in hepatocellular carcinoma and are potential targets for biological therapies. Oral Plenary Session III Society of Surgical Oncology 2006<br />11. Foster JM, Filacoma P, Brady B, Nava H, Hill H, Hicks W, Rigual N, Loree T, Gibbs JF. Defining the indications for prophylactic percutaneous endoscopic gastrostomy tubes in head and neck cancer patients. Society of Surgical Oncology 2006<br />12. Foster JM, Gatalica, Z, Lilleberg S, Haynatzki G, Loggie, BW. Novel and existing mutations in the EGF receptor tyrosine kinase domain are predictors of optimal resectability(OR) in malignant peritoneal mesothelioma(MPM). Winter Gastrointestinal American Society of Clinical Oncology (ASCO-GI) 2007<br />13. Foster JM, Gatalica, Z, Lilleberg S, Haynatzki G, Loggie, BW. Novel and existing mutations in the EGF receptor tyrosine kinase domain are predictors of optimal resectability(OR) in malignant peritoneal mesothelioma(MPM). Oral Session Second International Symposium on Regional Cancer Therapies. 2007<br />14. Foster JM, Gatalica, Z, Lilleberg S, Haynatzki G, Loggie, BW. Novel and existing mutations in the EGF receptor tyrosine kinase domain are predictors of optimal resectability(OR) in malignant peritoneal mesothelioma(MPM). Oral Session Society of Surgical Oncology 2007<br />15. Foster JM, Gatalica, Z, Lilleberg S, Haynatzki G, Loggie, BW. Novel and existing mutations in the EGF receptor tyrosine kinase domain are predictors of optimal resectability(OR) in malignant peritoneal mesothelioma(MPM). Oral (Discussion) Session American Society of Clinical Oncology (ASCO) 2007<br />16. Foster JM, Grotz TE, Turaga KK, Gatalica, Z, Sharma P, Loggie, BW. Analysis of immunohistochemical predictors of outcome in pseudomyxoma peritonei. Winter Gastrointestinal American Society of Clinical Oncology (ASCO-GI) 2008<br />17. Foster JM, El,-Abaseri T, Loggie BW. Novel illustration that MUC-2 over-expression promotes tumor growth by autocrine cellular events and signaling. Winter Gastrointestinal American Society of Clinical Oncology (ASCO-GI) 2008<br />18. Foster JM, Grotz TE, Turaga KK, Gatalica, Z, Sharma P, Loggie, BW. Analysis of immunohistochemical predictors of outcome in pseudomyxoma peritonei. Oral Session Third International Symposium on Regional Cancer Therapies. 2008<br />19. Foster JM, El,-Abaseri T, Loggie BW. Novel illustration that MUC-2 over-expression promotes tumor growth by autocrine cellular events and signaling. Oral Session Third International Symposium on Regional Cancer Therapies. 2008<br />20. Foster JM, Grotz TE, Turaga KK, Gatalica, Z, Sharma P, Loggie, BW. Analysis of immunohistochemical predictors of outcome in pseudomyxoma peritonei. Society of Surgical Oncology 2008<br /> 21. El,-Abaseri T, Foster JM, Loggie BW. MUC-2 over-expression promotes tumor growth by autocrine cellular events and signaling. American Association of Cancer Research 2008<br />22. Foster JM, Gupta P, Carreau J, Grotz TE, Gatalica, Z, Sharma P, Loggie, BW. Routine right hemicolectomy (RHC) may not be indicated in pseudomyxoma peritonei/mucinous appendiceal neoplasm (PMP/MAN). Winter Gastrointestinal American Society of Clinical Oncology (ASCO-GI) 2009<br />23. Foster JM, El-Abaseri T, Loggie BW. MUC-2 overexpression in colorectal cancer promotes tumor survival by regulation of Caspase-8 and akt expression. Winter Gastrointestinal American Society of Clinical Oncology (ASCO-GI) 2009<br />24. Foster JM, Uppala P, Govindarajan V, Carreau J, Gatalica, Z, Lillleberg S, Nath S, Loggie BW. Novel and existing activating EGFR mutations are predictive of a ‘relative’ improved survival in malignant peritoneal mesothelioma (MPM) and responsive to EGFR-TK inhibitors (EGFR-TKI). Oral Session Fourth International Symposium on Regional Cancer Therapies. 2009<br />25. Foster JM, Gupta P, Carreau J, Grotz TE, Gatalica, Z, Sharma P, Loggie, BW. Routine right hemicolectomy (RHC) may not be indicated in pseudomyxoma peritonei/mucinous appendiceal neoplasm (PMP/MAN). Oral Session Fourth International Symposium on Regional Cancer Therapies. 2009<br />26. Foster JM, El-Abaseri T, Loggie BW. MUC-2 overexpression in colorectal cancer promotes tumor survival by regulation of Caspase-8 and akt expression. Society of Surgical Oncology 2009<br />27. Lilleberg SL, Foster JM, Uppala R, Govindarajan V, Gatalica Z, Loggie BW. Malignant Peritoneal Mesotheliomas Harbor Somatic Mutations in EGFR, MET, and several Gate-Keeper Genes: Potential Predictive and Prognostic Markers for Focused Treatment Strategies. Society of Surgical Oncology 2009<br />28. Lilleberg SL, Foster JM, Uppala R, Govindarajan V, Gatalica Z, Loggie BW. Malignant Peritoneal Mesotheliomas Harbor Somatic Mutations in EGFR, MET, and several Gate-Keeper Genes: Potential Predictive and Prognostic Markers for Focused Treatment Strategies. American Association of Cancer Research (AACR) 2009<br />29. Lilleberg SL, Foster JM, Uppala R, Govindarajan V, Gatalica Z, Loggie BW. Analysis of PseudomyxomaPeritonei and Appendiceal Adenocarcinomas reveal Somatic Mutations of Key Genes within the MAPK, AKT, and WNT Signaling Pathways: Potential Prognostic and Predictive Markers for Focused Treatment Strategies. American Association of Cancer Research (AACR) 2009<br /> 30. Foster JM, Uppala P, Govindarajan V, Carreau J, Gatalica, Z, Lillleberg S, Nath S, Loggie BW. Novel and existing activating EGFR mutations are predictive of a ‘relative’ improved survival in malignant peritoneal mesothelioma (MPM) and responsive to EGFR-TK inhibitors (EGFR-TKI). Oral (Discussion) Session American Society of Clinical Oncology (ASCO) 2009<br />31. Foster JM, Uppala P, Govindarajan V, Carreau J, Gatalica, Z, Lillleberg S, Nath S, Loggie BW. Novel and existing activating EGFR mutations are predictive of a ‘relative’ improved survival in malignant peritoneal mesothelioma (MPM) and responsive to EGFR-TK inhibitors (EGFR-TKI). Oral. 10th Anunual Mesothelioma Foundation meeting 2010<br />Ad Hoc Journal Reviewer<br />Cancer<br />Annals of Surgical Oncology<br />Journal of Surgical Oncology<br />European Journal of Cancer<br />European Journal of Surgical Oncology<br />World Journal of Surgical Oncology<br />Tumor Biology<br />Asian-Pacific Journal of Hematology & Oncology<br />Hernia Journal<br />Invited Lectures <br />Contextual Effects of TGF on the tumorigenicity of Human Colon Carcinoma. Surgical Grand Rounds University Hospital of Cleveland, Case Western Reserve University 1997<br />The role of TGF in colon cancer tumorigenesis and progression. Surgical Grand Rounds University Hospital of Cleveland, Case Western Reserve University 1998<br />Management of function and non-functional neuroendocrine tumors of the pancreas. Oncology Lecture Series MetroHealth Medical Center, Case Western Reserve University 1999<br />Current management of congenital tracheal-esophageal fistulas. Pediatric Grand Rounds Cleveland Clinic/MetroHealth Medical Center, Case Western Reserve University 2000<br />Total Mesorectal Excision in the management rectal cancer is superior to Conventional resection with radiation. Oncology Lecture series MetroHealth Medical Center, Case Western Reserve University 2001<br />Current Management of Gallbladder: What have the past 50 years taught us? Roswell Park Cancer Institute Surgical Grand Rounds 2003 <br />The Role of Brachytherapy for sarcoma management. Roswell Park Cancer Institute Medical & Surgical Oncology joint lecture series 2004<br />Surgical management of hepatic neuroendocrine disease in the new millennium. Roswell Park Cancer Institute Surgical Grand Rounds 2004<br />Current Management of Gallbladder: What have the past 50 years taught us? State University of Buffalo Department of Surgery 2004<br />Advances in Breast cancer that have revolutionized the management of the disease. Fourth Annual Women Issues in the 21st Century sponsored by Creighton University October 7, 2005<br />Innovations in Surgical Oncology—Hyperthermic Therapy. Creighton University Department of Surgery Grand Rounds, June 12, 2006<br />Contemporary management of Melanoma & Sarcoma. Keynote Speaker at Metro Omaha Coder’s Association (MOCA) Creighton University November 10, 2006<br />The prevention and management of Skin and Colon Cancer. Senior Partner Seminar Creighton University January 27, 2007<br />Updates in Colorectal cancer detection and treatment. 2nd Annual: Surgical Techniques for Primary Care Physicians, Creighton University February 9, 2007<br />Diagnosis and management of Gastric and Pancreatic Cancer. Senior Partner Seminar Creighton University June 23rd, 2007<br />Diagnosis and management of melanoma and colorectal cancer. Offut Air Force base Family Practice Grand Rounds February 6th 2008<br />Translational Research in Surgical Oncology. Creighton University Department of Surgery Grand Rounds, May 19th, 2008<br />The prevention and management of colorectal cancer. Creighton Community Health Center Health Fair June 13th, 2008<br />Common Cancer in women: prevention, screening, and management. Women’s Health Conference June 21, 2008<br />Contemporary screening strategies in oncology. Creighton Community Health Center Health Seminar July 11, 2008<br />Translational Research: MUC-2 in PMP & EGFR mutations in Mesothelioma. Creighton University Department of Surgery presentation to visiting professor—Timothy R. Billiar MD July 21st, 2008<br />My Sister Keeper Annual Breast Cancer Survivor Banquet: Chaired Round Table Discussion on Contemperary management of Breast Cancer October 2008<br />The current role of CRS/IPHC in the management of appendix and colorectal peritoneal surface disease. UNMC 3rd Annual Thoracic and GI Conference September 30, 2009<br />Contemporary Management of Peritoneal Surface Malignancies- Part I (Appendix & Colorecal cancer). UNMC Grand Rounds December 16, 2009<br />Introduction to Peritoneal Surface Malignancies. UNMC OR Staff Education Conference March 17, 2010<br />Introduction to Peritoneal Surface Malignancies. UNMC ICU Staff Education Conference April 7 & 8, 2010<br />Contemporary Management of Peritoneal Surface Malignancies- Part (Appendix & Colorecal cancer). CUMC Grand Rounds April 17, 2010<br />Role of EGFR in Heaptocellular and Mesothelioma abdominal carcinomas. . Department of Surgery Weekly Research Forum May 26 2010<br />Introduction to Peritoneal Surface Malignancies. UNMC OR Peri-operative Staff Education Conference April 7 & 8, 2010<br />Introduction to Peritoneal Surface Malignancies. UNMC Oncology Nursing Staff Education Conference April 7 & 8, 2010<br />

×